New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
暂无分享,去创建一个
[1] Hereditary papillary renal cell carcinoma , 2020, Definitions.
[2] P. Lowe,et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome , 2015, The Medical journal of Australia.
[3] G. Mills,et al. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis , 2014, Oncogene.
[4] S. Sarkar,et al. SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability , 2014, Cell reports.
[5] G. Mills,et al. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. , 2014, Cancer research.
[6] J. Desterro,et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint , 2014, eLife.
[7] J. Cheville,et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low‐risk clear cell renal cell carcinoma , 2014, Cancer.
[8] W Marston Linehan,et al. Intratumoral heterogeneity in kidney cancer , 2014, Nature Genetics.
[9] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[10] Joel S Parker,et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects , 2014, Genome research.
[11] W. Linehan,et al. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. , 2013, Seminars in oncology.
[12] R. Motzer,et al. Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma , 2013, Cancer journal.
[13] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[14] G. Gyapay,et al. Germline BAP1 mutations predispose to renal cell carcinomas. , 2013, American journal of human genetics.
[15] N. Grishin,et al. A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma , 2013, Molecular Cancer Research.
[16] W Marston Linehan,et al. Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer , 2013, Clinical Cancer Research.
[17] C. Sander,et al. Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.
[18] Wei Yang,et al. The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.
[19] Karl J. Dykema,et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. , 2013, Cancer research.
[20] G. Stephanopoulos,et al. Cofactor Balance by Nicotinamide Nucleotide Transhydrogenase (NNT) Coordinates Reductive Carboxylation and Glucose Catabolism in the Tricarboxylic Acid (TCA) Cycle*♦ , 2013, The Journal of Biological Chemistry.
[21] G. Stephanopoulos,et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.
[22] W. Kaelin,et al. The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.
[23] R. Srinivasan,et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W Marston Linehan,et al. Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics , 2012, Genome research.
[25] James B. Mitchell,et al. Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma , 2012, Oncotarget.
[26] T. Grkovic,et al. Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. , 2012, Journal of natural products.
[27] R. Motzer,et al. Ten years of progress in renal cell carcinoma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[28] N. Grishin,et al. BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.
[29] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[30] Huanming Yang,et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.
[31] Christian M. Metallo,et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.
[32] E. Jonasch,et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis , 2011, Modern Pathology.
[33] Ximing J. Yang,et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. , 2011, Cancer cell.
[34] P. Carmeliet,et al. Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.
[35] W. Marston Linehan,et al. Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.
[36] R. Sougrat,et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.
[37] Rameen Beroukhim,et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. , 2011, Cancer discovery.
[38] Xiuping Liu,et al. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. , 2011, Cancer research.
[39] K. Gustafson,et al. Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. , 2011, Bioorganic & medicinal chemistry letters.
[40] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[41] B. Viollet,et al. AMPK as a therapeutic target in renal cell carcinoma , 2010, Cancer biology & therapy.
[42] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[43] W. Linehan,et al. The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.
[44] Benjamin L Ebert,et al. The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. , 2010, Cancer research.
[45] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[46] W. Linehan,et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.
[47] T. Golub,et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. , 2008, Molecular cell.
[48] G. Powis,et al. Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation , 2008, Molecular and Cellular Biology.
[49] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[50] J. Engelman,et al. A sweet new role for EGFR in cancer. , 2008, Cancer cell.
[51] P. Choyke,et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. , 2007, The Journal of urology.
[52] W. Linehan,et al. Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression , 2006, Journal of biomolecular screening.
[53] Yuen-Li Chung,et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.
[54] O. Iliopoulos,et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.
[55] W. Kaelin,et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.
[56] A. Paetau,et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.
[57] Mirna Lechpammer,et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.
[58] Richard D Klausner,et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.
[59] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[60] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[61] L. Aaltonen,et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[62] P. Choyke,et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.
[63] W. Marston Linehan,et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.
[64] P. Choyke,et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.
[65] S. Scherer,et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.
[66] D. Duan,et al. Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.
[67] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[68] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[69] J. Graham,et al. METABOLISM OF CANCER CELLS , 1955 .
[70] Paolo Vineis,et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 , 2011, Nature Genetics.
[71] W. Linehan,et al. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. , 2011, Chemical & pharmaceutical bulletin.
[72] W. Linehan,et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. , 2010, Cancer genetics and cytogenetics.